Alnylam Pharmaceuticals
ALNY
#663
Rank
A$47.00 B
Marketcap
$364.41
Share price
-8.67%
Change (1 day)
38.72%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -A$0.28 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$2.09 Billion. In 2023 the company made an earning of -A$0.49 Billion, an increase over its 2022 earnings that were of -A$1.51 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -A$0.28 Billion-43.3%
2023 -A$0.49 Billion-67.84%
2022 -A$1.51 Billion36.93%
2021 -A$1.1 Billion-8.04%
2020 -A$1.2 Billion-15.66%
2019 -A$1.42 Billion12.23%
2018 -A$1.27 Billion62.91%
2017 -A$0.78 Billion17.78%
2016 -A$0.66 Billion43.44%
2015 -A$0.46 Billion60.69%
2014 -A$0.29 Billion98.2%
2013 -A$0.15 Billion
2011 -A$84.81 Million27.48%
2010 -A$66.53 Million-10.92%
2009 -A$74.68 Million95.77%
2008 -A$38.15 Million
2006 -A$61.11 Million-9.13%
2005 -A$67.26 Million34.74%
2004 -A$49.92 Million36.79%
2003 -A$36.49 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-A$0.82 Billion 181.30%๐Ÿ‡บ๐Ÿ‡ธ USA
A$7.68 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
A$96.25 M-133.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$0.38 Billion 30.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$54.15 Million-81.27%๐Ÿ‡บ๐Ÿ‡ธ USA
A$19.69 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$11.45 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
A$1.27 B-542.53%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel